Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Harvard Business School
McKinsey
Johnson and Johnson
Baxter

Last Updated: June 25, 2022

Litigation Details for CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD. (D.N.J. 2019)


✉ Email this page to a colleague

« Back to Dashboard

CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD. (D.N.J. 2019)

Small Molecule Drugs cited in CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.
The small molecule drugs covered by the patents cited in this case are See Plans and Pricing , See Plans and Pricing , and See Plans and Pricing .
Biologic Drugs cited in CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.

Details for CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD. (D.N.J. 2019)

Date Filed Document No. Description Snippet Link To Document
2019-07-12 1 Complaint 6,045,501 A 4/2000 Elsayed et al. …8,673,939 (the “’939 patent”), 8,735,428 (the “’428 patent”), 8,828,427 (the “’427 patent”), and 9,993,467… 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C…the expiration of United States Patent Nos. 8,198,262 (the “’262 patent”), Case 2:19-cv-15343-ES-MAH Document…9,993,467 (the “’467 patent”), all owned by Celgene (collectively, “the patents-in-suit”). External link to document
2022-01-27 145 Letter 10,093,648; 10,093,649; and 10,555,939 and (2) a Final Judgment Regarding U.S. Patent Nos. 8,198,262 and 8,…10,093,649; and 10,555,939. 4. Until expiration of the Patents-in-Suit, DRL, including… others, U.S. Patent Nos. 8,198,262 (the “’262 patent”) and 8,828,427 (the “’427 patent”), and pursuant… the ’262 patent is valid, enforceable, entitled to the patent term adjustments and patent term extensions…262 patent as well as the propriety and enforceability of the patent term adjustments and patent term External link to document
2022-02-22 148 Order FINAL JUDGMENT REGARDING U.S. PATENT NOS. 8,198,262 AND 8,828,427, etc. Signed by Judge Esther … 12 July 2019 2:19-cv-15343 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
McKesson
Harvard Business School
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.